Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 4
1974 1
1975 1
1976 1
1977 1
1978 1
1999 5
2000 2
2001 6
2002 4
2003 1
2004 2
2005 1
2006 3
2007 1
2008 1
2009 4
2010 3
2011 3
2012 8
2013 7
2014 7
2015 4
2016 4
2017 14
2018 11
2019 11
2020 16
2021 21
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

133 results
Results by year
Filters applied: . Clear all
Page 1
Cutaneous T cell lymphoma.
Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, Geskin LJ, Quaglino P, Ramelyte E. Dummer R, et al. Among authors: scarisbrick jj. Nat Rev Dis Primers. 2021 Aug 26;7(1):61. doi: 10.1038/s41572-021-00296-9. Nat Rev Dis Primers. 2021. PMID: 34446710 Review.
Update on skin directed therapies in mycosis fungoides.
Lovgren ML, Scarisbrick JJ. Lovgren ML, et al. Among authors: scarisbrick jj. Chin Clin Oncol. 2019 Feb;8(1):7. doi: 10.21037/cco.2018.11.03. Epub 2018 Nov 28. Chin Clin Oncol. 2019. PMID: 30525757 Free article. Review.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Among authors: scarisbrick j. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Horwitz SM, et al. Among authors: scarisbrick jj. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. Blood Adv. 2021. PMID: 34507350 Free PMC article. Clinical Trial.
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke CD, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R. Trautinger F, et al. Among authors: scarisbrick j. Eur J Cancer. 2017 May;77:57-74. doi: 10.1016/j.ejca.2017.02.027. Epub 2017 Mar 31. Eur J Cancer. 2017. PMID: 28365528 Free article. Review.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Among authors: scarisbrick j. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, Papadavid E, Evison F, Knobler R, Quaglino P, Vermeer MH. Scarisbrick JJ, et al. Eur J Cancer. 2018 Apr;93:47-56. doi: 10.1016/j.ejca.2018.01.076. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477101 Free article. Review.
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Olsen EA, et al. Among authors: scarisbrick j. Blood. 2022 Aug 4;140(5):419-437. doi: 10.1182/blood.2021012057. Blood. 2022. PMID: 34758074
New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ. Scarisbrick JJ. Curr Opin Oncol. 2016 Sep;28(5):384-9. doi: 10.1097/CCO.0000000000000311. Curr Opin Oncol. 2016. PMID: 27390044 Review.
133 results